tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2021 (NCT04842812)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
- Glypican-3Immunity, passive
immunity, passive - gpc3
- UnclearImmunity, passive
Unclear immunity, passive
- Mucin-1Immunity, passive
MUC1 immunity, passive
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
- Claudin-18Immunity, passive
CLDN18 immunity, passive
- Tyrosine-protein kinase receptor UFOImmunity, passive
AXL immunity, passive
- Tyrosine-protein kinase transmembrane receptor ROR1Immunity, passive
ROR1 immunity, passive
- Prostate stem cell antigenImmunity, passive
PSCA immunity, passive
- MesothelinImmunity, passive
MSLN immunity, passive
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04842812 | Phase 1 | Jan 1, 2021 | Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Guangzhou Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangdong Zhaotai InVivo Biomedicine Co. Ltd. | Government | 1 | 0 | 1 | 2021 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1